Research Portfolio

Funding Opportunities

Join our Mailing List
Join our mailing list to be notified of new funding opportunities.

Your Email

To receive information about funding opportunities, events, and program updates.



Kostyantyn Krysan, Ph.D.

University of California, Los Angeles # of Grants: 2

Grants

COX-2-dependent modulation of survivin in lung cancer 2003 (Cycle 12) $69,500
Cancer Postdoctoral Fellowship Awards

Mechanisms of targeted therapy resistance in lung cancer 2006 (Cycle 15) $358,500
Cancer Research Project Awards
Publications

COX-2-dependent stabilization of survivin in non-small cell lung cancer.
Periodical: FASEB Journal Index Medicus:
Authors: Krysan K, Merchant F, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Pold M, et. al ART
Yr: 2004 Vol: 18 Nbr: Abs: Pg: 206-208

COX-2-dependent expression of survivin is critical for apoptosis resistance in NSCLC.
Periodical: Cancer Research Index Medicus:
Authors: Drysan K, Dalwadi H, Sharma S, Pold M, Dubinett SM ART
Yr: 2004 Vol: 64 Nbr: Abs: Pg: 6359 - 6362

Cyclooxygenase-2-Dependent expression of survivin in non-small cell lung cancer.
Periodical: Chest Index Medicus:
Authors: Drysan K, Dohadwalala M, Luo J, Lin Y, Zhu L, et al ART
Yr: 2004 Vol: 125 Nbr: Abs: Pg: 140S

Multifaceted roles of cyclooxygenase-2 in lung cancer.
Periodical: Drug Resistance Updates Index Medicus:
Authors: Riedl K, Drysan K, Pold M, Dalwadi H, et al ART
Yr: 2004 Vol: 7 Nbr: Abs: Pg: 169 - 174

PGE2 activates MAPK/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an EGF receptor-independent manner.
Periodical: Cancer Research Index Medicus:
Authors: Krysan K, Reckamp KL, Dalwadi H, Sharma S, Dohadwala M, Dubinett SM ART
Yr: 2005 Vol: 65 Nbr: Abs: Pg: 6275 - 6281

PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells.
Periodical: Journal of Leukocyte Biology Index Medicus:
Authors: Baratelli F, Krysan K, Heuze-Vourc'h N, Zhu L, et al ART
Yr: 2005 Vol: 78 Nbr: Abs: Pg: 555 - 564

COX-2 dependent STAT3 activation by IL-6 in non-small cell lung cancer.
Periodical: Clinical Cancer Research Index Medicus:
Authors: Dalwadi H, Drysan K, Heuze-Voure'h N, Pold M, Elashoff D, et al ART
Yr: 0 Vol: Nbr: Abs: Pg:

Cyclooxygenase-2-dependent regulation of E-cadherin expression PGE2 induces E-cadherin transcriptional repressors ZEB1 and SNAIL in NSCLC.
Periodical: Cancer Research Index Medicus:
Authors: Krysan K ART
Yr: 2006 Vol: Nbr: 66 Abs: Pg: 5338-5345

The Potential and Rationale for COX-2 Inhibitors in Lung Cancer
Periodical: Curr. Med. Chem Index Medicus:
Authors: Krysan K, Reckamp KL, Sharma S, Dubinett SM ART
Yr: 2006 Vol: 6 Nbr: Abs: Pg: 209-220

A phase I Trial to Determine the optimal Biologic Dose of Celecoxib when Combineed with Erlotinib in Advanced Non-Small Cell Lung Cancer.
Periodical: Clinical Cancer Research Index Medicus:
Authors: Krysan K ART
Yr: 2006 Vol: Nbr: 12 Abs: Pg: 3381-3388

Significance of cyclooxygenase -2 in prognosis targeted therapy and chemoprevention of NSCLC.
Periodical: Future Cardiol Index Medicus:
Authors: Krysan K ART
Yr: 2007 Vol: Nbr: 3 Abs: Pg: 149-153

Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase (MMP)-9 and a decline in serum
Periodical: Journal of Thoracic Oncology Index Medicus:
Authors: Reckamp, K.L., Gardner, B.K., Figlin, R.A., Elashoff, D., Krysan, K., Dohadwala, M., Mao, ART
Yr: 2007 Vol: 3 Nbr: Abs: Pg: 117-124

Inflammation and lung carcinogenesis: applying new findings in prevention and treatment
Periodical: Expert Review of Anticancer Therapy Index Medicus:
Authors: Peebles, K.A., Lee, J.M., Mao, J.T., Hazra, S., Reckamp, K.L., Krysan, K., Dohadwala, M. ART
Yr: 2007 Vol: 7 Nbr: Abs: Pg: 1405-1421

Inflammation, EMT and EGFR TKI resistance
Periodical: Journal of Thoracic Oncology Index Medicus:
Authors: Krysan, K., Lee, J.M., Dohadwala, M., Gardner, B.K., Reckamp, K.L., Garon, E., St. John, M ART
Yr: 2008 Vol: 3 Nbr: Abs: Pg: 107-110